Skip to content

Kardigan

US · KARD #3042 by market cap Listed 2026
11.54 -0.98 -7.83%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 2.26 In line with history 66th percentile
5-year average -0.59 · #263 of 513 in Biotechnology
P/E ratio -4.50 Expensive vs history 83rd percentile
5-year average -6.21 · forward -3.84
P/S ratio --
5-year average 0.00 · forward 4,624.46

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Kardigan (KARD) 1.08B -3.76 1.89 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value22.62 Economic moatNone UncertaintyVery High

Trading 96.0% below Morningstar's fair value estimate.

Fair value

Kardigan Inc is assigned a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 39% discount to our quantitative fair value estimate of $22.62 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 2.4, which lies in the bottom 30% compared with peers globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.

Conversely, the company's balance sheet is potentially concerning. Low leverage can limit a company's ability to invest in growth, potentially reducing shareholder value compared with a balanced use of debt and equity financing. The firm's long term debt to assets ratio of 0.01, a core component of leverage, sits in the bottom 30% globally. With little long-term debt relative to assets, this firm has a "lazy" balance sheet, which can depress returns on invested capital. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.

Kardigan discussion 0 comments

Add a comment